Top Analyst Reports For Intel, Oracle & Novo Nordisk

 | Oct 15, 2019 12:59AM ET

Tuesday, October 15, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Oracle (ORCL) and Novo Nordisk (CSE:NOVOb) (NVO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see

Intel’s shares have outperformed the Zacks General Semiconductor industry year to date (3.1% vs. -6.4%). The Zacks analyst believes that Intel is benefiting from rising demand witnessed in its higher performance products, both in data center and client domains.

Moreover, synergies from its Mobileye (F:0ME) acquisition and growing clout in ADAS market favor the company’s growth prospects. Further, Intel’s strategy of expanding TAM beyond CPU to adjacent product lines like silicon photonics, fabric, network ASICs, and 3D XPoint memory is yielding results.

The launch of its new 10nm-technology-based AI chip, Springhill, holds promise. However, weakness in demand from China and softness in NAND flash pricing trends, expenses pertaining to 10-nanometer (nm) ramp and constrained supply remain major concerns. Moreover, intensifying competition and pricing pressure from AMD remains a headwind.

(You can )

Shares of Oracle have gained 3.4% in the past six months, compared with the Zacks Computer Software industry’s rise of 8.2%. The Zacks analyst believes that Oracle is benefiting from strong adoption of cloud-based solutions, comprising NetSuite ERP, Fusion ERP and Fusion HCM, among others.

Partnerships with the likes of Accenture (NYSE:ACN) and Microsoft (NASDAQ:MSFT) are expected to aid Oracle in expanding cloud-based clientele. Moreover, strong demand for the latest autonomous database supported by ML is likely to bolster the top line and provide a competitive edge against Amazon (NASDAQ:AMZN) Web Services (AWS) in the Database-as-a-Service market.

Nonetheless, stiff competition in the cloud market from dominant players is anticipated to weigh on profits. Further, lower hardware volumes are expected to hurt the top line, keeping margins under pressure. Additionally, integration risks from buyouts remain a concern. Notably, shares of Oracle have underperformed the industry in the past year.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

(You can )

Novo Nordisk’s shares have gained 9% over the past three months, compared with the Zacks Biotech industry’s rise of 0.4%. The Zacks analyst believes a solid performance from Tresiba, Victoza, Ozempic, Xultophy and Saxenda have driven the company’s sales in the year so far.

Label expansion of Victoza continues to boost performance. Ozempic, the company’s once-weekly GLP-1, continues to gain market share. The FDA recently approved semaglutide in tablet form under the brand name, Rybelsus. The company continues to evaluate the candidate for multiple indications. Shares of the company have outperformed the industry year to date.

However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition within the diabetes and biopharmaceuticals markets will adversely impact sales, going ahead.

(You can )

Other noteworthy reports we are featuring today include ConocoPhillips (NYSE:COP) (COP), Occidental Petroleum (OXY) and Advanced Micro Devices (NASDAQ:AMD) (AMD).

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly

Today's Must Read/h6

Featured Reports/h6

The Zacks analyst believes that ConocoPhillips' Australia-West asset divestment, including the Athena field, is likely to enable it to generate more value from US shale amid surging operating costs.

Per the Zacks analyst, Advanced Micro's release of Radeon RX Vega family of GPUs and alliance with companies like Baidu (NASDAQ:BIDU), Amazon, Tencent, Microsoft and JD.com will drive the top and bottom line.

Per the Zacks Analyst, CBRE Group will ride high on buyouts that expand and reinforce service offerings and enhance geographic reach.

AmerisourceBergen gains ground on its World Courier business. The Zacks Analyst is pessimistic about cutthroat competition in the MedTech Space.

The Zacks analyst likes Cheniere's competitive advantage of being the first and dominant natural gas exporter in the U.S. market.

Per the Zacks analyst, its growing revenues driven by premium growth and accretive acquisitions has led to significant growth.

Per the Zacks Analyst, strategic acquisitions will boost Jones Lang LaSalle's business and drive inorganic growth. Yet, low real estate transaction volumes is a concern.

New Upgrades/h6

Per the Zacks analyst, Skechers' international wholesale business remains a key sales driver. Management expects international business to increase at a mid-teens rate over the balance of the year.

The Zacks analyst is impressed by the robust rise in passenger unit revenues on the back of strong travel demand. The company's focus on capacity discipline is also aiding its performance.

Per the Zacks analyst, Cohen & Steers' revenues will continue to grow driven by robust assets balance, diverse product offerings and investment strategies. Its capital deployments remain impressive.

New Downgrades/h6

Per the Zacks analyst Occidental's margins could be adversely impacted by the rising global freight rates due to the U.S. sanction on Chinese supertanker operators.

Per the Zacks analyst, pressure on investment management fees amid muted AUM growth along with impact of new regulations continue to pose concerns for Franklin.

Per the Zacks Analyst, higher maintenance costs owing to annual shutdowns of major facilities, rising raw material costs and unfavorable foreign currency will impact Domtar's results.


undefined Zacks Investment Research

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes